• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Bioorg Chem . Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding c

tetano

Editor, Senior Moderator
Bioorg Chem


. 2024 Jan 19:144:107139.
doi: 10.1016/j.bioorg.2024.107139. Online ahead of print. Optimization and biological evaluation of l-DOPA derivatives as potent influenza PA[SUB]N[/SUB] endonuclease inhibitors with multi-site binding characteristics

Jiaai Ruan[SUP] 1 [/SUP], Kunyu Lu[SUP] 2 [/SUP], Jianfu He[SUP] 2 [/SUP], Yihao Chen[SUP] 1 [/SUP], Baixi Li[SUP] 1 [/SUP], Xin Wan[SUP] 3 [/SUP], Xiao Chen[SUP] 1 [/SUP], Sumei Li[SUP] 4 [/SUP], Shuwen Liu[SUP] 5 [/SUP], Gaopeng Song[SUP] 6 [/SUP]



Affiliations
Abstract

Emerging and potential influenza pandemics still are an enormous worldwide public health challenge. The PA[SUB]N[/SUB] endonuclease has been proved to be a promising target for anti-influenza drug design. Here, we report the discovery and optimization of potent Y-shaped PA[SUB]N[/SUB] inhibitors featuring multi-site binding characteristics with l-DOPA as a starting point. We systematically modified the hit 1 bearing two-binding characteristics based on structure-based rational design combined with multisite binding and conformational constraint strategies, generating four families of l-DOPA derivatives for SARs analysis. Among these substances, N, 3-di-substituted 1, 2, 3, 4-tetrahydroisoquinoline derivative T-31 displayed superior properties as a lead PA[SUB]N[/SUB] endonuclease inhibitor and antiviral agent. The lead T-31 inhibited PA[SUB]N[/SUB] endonuclease activity with an IC[SUB]50[/SUB] value of 0.15 μM and showed broad and submicromolar anti-influenza potency in cell-based assays. More importantly, T-31 could simultaneously target both influenza HA and the RdRp complex, thus interfering with virus entry into host cells and viral replication. This study offers a set of novel PA[SUB]N[/SUB] endonuclease inhibitors with multi-site binding characteristics starting from the l-DOPA skeleton.

Keywords: Influenza A virus; PA(N) endonuclease inhibitors; Structure–activity relationship; l-DOPA derivatives.

 
Back
Top Bottom